Cisplatin is a potent chemotherapeutic used for the treatment of many types of cancer. However, its dose-limiting side effect is nephrotoxicity leading to acute kidney injury (AKI) (29, 30). Patients who develop AKI have an increased risk of mortality and are more likely to develop chronic kidney disease (CKD) (5, 14, 31). Unfortunately, there are no therapeutic interventions for the treatment of AKI. It has been suggested that the lack of therapies is due in part to the fact that the established mouse model used to study cisplatin-induced AKI does not recapitulate the cisplatin dosing regimen patients receive (41). In recent years, work has been done to develop more clinically-relevant models of cisplatin-induced kidney injury, with much work focusing on incorporation of multiple, low doses of cisplatin administered over a period of weeks. These models can be used to recapitulate the development of CKD after AKI, and by doing so, increase the likelihood of identifying novel therapeutic targets for the treatment of cisplatin-induced kidney injury.